RecruitingPhase 3NCT06003387
Blood
Moderate hemophilia B
5
studies recruiting now
as of 7 Sept 2026
38
studies registered in total
as of 7 Sept 2026
32
countries with a recruiting site
as of 7 Sept 2026
23 Jul 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT05611801
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RecruitingPhase 1 / Phase 2NCT06379789
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RecruitingPhase 3NCT07080905
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RecruitingPhase 3NCT05145127
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Moderate hemophilia B studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Moderate hemophilia B study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Moderate hemophilia B
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (F9).
Treatments being studied
13 approved treatments and 9 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Coagulation Factor Ix Human (Coagulation factor ix human component of balfaxar)Approved: Characterised Viable Autologous Cartilage Cells Expanded Ex Vivo Expressing Specific Marker Proteins (Chondrocelect)Approved: Albutrepenonacog Alfa (Idelvion)Approved: Nonacog Beta Pegol (Refixia)Approved: Etranacogene Dezaparvovec (Hemgenix)Approved: Coagulation Factor Ix Recombinant Human (Benefix)Approved: Eptacog Beta (Activated) (Cevenfacta)Approved: Concizumab (Alhemo)Approved: Spheroids Of Human Autologous Matrix-Associated Chondrocytes (Spherox)Approved: Eftrenonacog Alfa (Alprolix)Approved: Eptacog Alfa (Activated) (Novoseven)Approved: Fidanacogene Elaparvovec (Beqvez)Approved: Marstacimab (Hympavzi)
Phase 3Anti-Inhibitor Coagulant Complex
Phase 3Trenonacog Alfa (Ixinity[tm])
Phase 3Vatreptacog Alfa (Activated)
Phase 3Fitusiran
Phase 2Bay-1093884
Phase 2Eptacog Alfa Pegol (Activated)
Phase 2Ataluren (Translarna)
Phase 1/2Verbrinacogene Setparvovec
+ 1 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).